ImpriMed
AI-driven personalized drug response predictions for pet cancer
About
ImpriMed is a precision-medicine service for dogs and cats with blood cancers like lymphoma and leukemia. The vet ships live cancer cells and blood samples to ImpriMed's California lab, where drug-sensitivity measurements are combined with AI models trained on clinical outcome data to predict which anticancer drugs will likely work for that patient. Results arrive within six to seven days per the company's announcement; it is a lab service ordered through the veterinarian, not a product a pet owner buys directly, and it covers specific cancer types rather than all oncology cases.
What it can do
- AI-based drug response predictions for canine lymphoma/leukemia
- CHOP prognosis and single-drug response predictions
- Clonality testing by PARR assay
- Published peer-reviewed clinical outcome data
Setup
- A veterinarian evaluates the patient and orders the ImpriMed service
- Collect live cancer cells and blood samples per ImpriMed's kit instructions
- Ship samples overnight to the California laboratory
- Receive the Personalized Prediction Profile or DRP report within 6-7 days
- Use the drug response predictions to select the treatment protocol
Prerequisites
A treating veterinarian or oncologist to order and interpret the service
Use cases
Works with
Trust score — 7/10
Scored 7/10 (verified tier, metrics-v1). Evidence: ImpriMed verified via official imprimedicine.com press release (Drug Response Predictions launch) and Pulse2 company profile today.; Service is lab-based: vet ships live cancer cells to California lab, report in 6-7 days; AI combines drug-sensitivity measurements with clinical data.; Peer-reviewed publications and patient counts are company-reported; service covers specific blood cancers, not all oncology.. License: B2B lab service ordered through a veterinarian; not a consumer product..
How the trust score is built
Full methodology →- Adoption · stars/downloads, log-scaled vs peers
- 7.0/10
- Maintenance · recency, releases, issue load
- 7.0/10
- Openness · license + docs
- 6.0/10
- Manual review · sanity read + red-flag check
- 8.0/10
- · ImpriMed verified via official imprimedicine.com press release (Drug Response Predictions launch) and Pulse2 company profile today.
- · Service is lab-based: vet ships live cancer cells to California lab, report in 6-7 days; AI combines drug-sensitivity measurements with clinical data.
- · Peer-reviewed publications and patient counts are company-reported; service covers specific blood cancers, not all oncology.
Sources
Every fact above was checked against these sources. Where a claim comes from the provider and couldn't be independently verified, the text says so.